Skip to main content

A Day 1 recap of the Cannabis Law Institute by The D.C. Bar Blog - #CLI2022

 


Facing Inconsistent Government Regulation, Cannabis Industry Aims for Doable Reforms - #CLI2022

Original article posted June 14, 2022, by Jeremy Conrad and John Murph, on Duly Noted, The D.C. Bar Blog

With expanded legalization and growing capital, the cannabis industry is projected to reach $33.6 billion in global sales by 2025, but the uneven policy landscape in the United States continues to pose challenges to businesses, communities, and state and local governments.

At the International Cannabis Bar Association’s fifth annual Cannabis Law Institute on June 9–11, attendees discussed the impacts of federal prohibition on the cultivation, sale, and use of marijuana as well as the lack of uniform cannabis regulation in the country. These inconsistent policies put the District of Columbia, for example, in a confusing and sometimes dangerous territory, said D.C. Attorney General Karl Racine, who delivered the keynote address.

Unlike many states, the District cannot have a recreational cannabis marketplace where it can regulate and collect tax, limit toxicity, restrict advertisement from children, and enforce other common sense law practices. “Those kinds of must-haves in a regulatory scheme have been precluded by Congress because [the District] lacks statehood,” Racine said.

In response, ... (Read full article on Duly Noted)

Popular posts from this blog

Cannabis Branding: On the Edge of the Metaverse

Photo by julien Tromeur on Unsplash Branding in the Metaverse is all the rage. In the last three months alone, well-known brands like Nike, Converse, New Balance, Vineyard Vines, Tahari, Anthropologie, Hollister, Abercrombie & Fitch, and, even Walmart, have all filed applications with the United States Patent and Trademark Office  for intent-to-use trademarks in connection with “digital goods;”# opportunistic filings by individuals not affiliated with name brands have appeared in Classes 9, 35, and 41# for both PRADA and GUCCI; and Metaverse Law, a clever California law firm has been diligently going through the motions in their attempt to trademark the very word on everyone’s lips. But what is Metaverse, and why should you, the owner of the expertly cultivated flower brand, or producer of the most delicately infused edibles care? Metaverse is a virtual world meant to support decentralized, persistent three-dimensional environments, and accessible by anyone with a smart phone, gam

DOES NEW YORK HAVE A RESIDENCY REQUIREMENT FOR CANNABIS LICENSEES?

  By Andrew Kingsdale (published here with permission) Originally published February 3, 2022 on the blog of the Law Offices of Omar Figueroa Does one have to be a New York resident to own or manage a New York state-licensed cannabis business?  No, but the license applicant does need to have a certain nexus to the state.  With certain exceptions, non-residents may use a business or other legal entity to satisfy the nexus requirements. We start with definition of an “applicant”under New York’s new cannabis law, the Marijuana Regulation and Taxation Act (MRTA): “Applicant” unless otherwise specified in this chapter, shall mean a person applying for any cannabis, medical cannabis or cannabinoid hemp license or permit issued by the New York state cannabis control board pursuant to this chapter that: has a significant presence in New York state, either individually or by having a principal corporate location in the state; is incorporated or otherwise organized under the laws of this state; o

Diversity in the Cannabis Industry - it's more than checking the box

  June 30, 2022 12:30-2PM Eastern/11:30AM-1PM Central CICK HERE TO REGISTER Discover what your clients are missing about diversity in the cannabis industry – including how to address issues unique to this industry. You will hear from a diverse panel of cannabis business owners and executives about their experiences and learn tips for keeping your clients on the right side of this issue. Prep for this with this article from Marijuana Business Journal found in The Cannabis NewsHub . We are proud to be content providers and supporters of ABA Moderator:   Susan Burns , S Burns Legal PLLC Panelists: Steven Brown , CEO, Nothing But Hemp LLC Angela Dawson , CEO and co-founder, 40 Acres Co-op Amber Littlejohn , Executive Director, Minority Cannabis Business Association Maggie May Wilson , CMO, Fruit Slabs Lici Zimmerman Co-Sponsored by the ABA TIPS Cannabis Committee

Risk & Regulatory Intervention in the UK Cannabis Sector

Click to Watch (Recorded Feb 24th, 2022) Gain an overview of the UK Cannabis markets, including an overview of the small but growing medical segment, as well as the booming CBD and wellness industries. Attendees will also learn about the larger dynamics of EU regulations and how it impacts the domestic UK markets, including the novel foods analysis and import/export of products both from North American and into the rest of Europe. Finally we will see what is up next for the UK - the permissibility of hemp flower, Adult Use on the horizon, and other issues that will affect the future of the cannabis industry in the UK.

The Future of FDA and Cannabis Regulation (now available for On-Demand CLE)

Regulation of cannabis by the federal government , specifically the Food & Drug Administration, was unthinkable less than a decade ago, but it will someday soon be a reality. The FDA is already aware of the non-approved uses of cannabis to treat conditions such as AIDS wasting, epilepsy, neuropathic pain, and several others. The agency has also approved one cannabis-derived drug product: Epidiolex (cannabidiol), used to treat seizures, and three synthetic cannabis-related drug products: Marinol (dronabinol), Syndros (dronabinol), and Cesamet (nabilone), all of which treat nausea due to chemotherapy. These approvals don’t signal a trend toward legalization of cannabis, but they do show that the FDA’s studies of cannabis are starting to bear some fruit. The most recent official guidance from the FDA regarding cannabis regulation was published in January 2021. In this communication, the FDA reassured readers that they are aware of the public interest in using cannabis to develop treat

Disclaimer:

The information on this blog is provided for educational purposes and are not intended as legal advice. INCBA’s website(s) includes facts, views, opinions, and recommendations of third parties deemed to be of interest. INCBA does not guarantee the accuracy, reliability, completeness, or timeliness of, or otherwise endorse these views, opinions, or recommendations. You acknowledge that any reliance upon any such opinion, advice, statement, memorandum, or information shall be at your own risk.